News
-
-
COMMUNIQUÉ DE PRESSE
CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
CureVac to present at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, sharing immunogenicity data on mRNA-based cancer vaccine CVGBM. Conference details and contact info provided -
-
-
COMMUNIQUÉ DE PRESSE
CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress
CureVac's CVGBM Cancer Vaccine induces promising immune responses in Phase 1 Study in Glioblastoma presented at ESMO 2024 Congress. Results show de novo T-cell activity & acceptable safety profile up to 100 µg dose -
-
-
-
-
